Who are rosiglitazone (4 mg)/day's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Rosiglitazone XR, Placebo then Pioglitazone, metformin\pioglitazone\exenatide, Pioglitazone + Metformin, Rosiglitazone/alpha-lipoic acid, Dapagliflozin/Pioglitazone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rosiglitazone-4-mg-day.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

rosiglitazone (4 mg)/day — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

rosiglitazone (4 mg)/day (rosiglitazone (4 mg)/day) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thiazolidinedione. Area: Diabetes.

phase 3 Thiazolidinedione PPAR-γ Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

rosiglitazone (4 mg)/day (rosiglitazone (4 mg)/day) — National Cheng-Kung University Hospital. Rosiglitazone activates PPAR-γ, leading to increased insulin sensitivity and glucose uptake in adipose tissue.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
rosiglitazone (4 mg)/day TARGET	rosiglitazone (4 mg)/day	National Cheng-Kung University Hospital	phase 3	Thiazolidinedione	PPAR-γ
Rosiglitazone XR	Rosiglitazone XR	GlaxoSmithKline	marketed	Thiazolidinedione (PPAR-γ agonist)	PPAR-γ (Peroxisome proliferator-activated receptor gamma)
Placebo then Pioglitazone	Placebo then Pioglitazone	Medical University of South Carolina	marketed	Thiazolidinedione	PPAR-γ (Peroxisome proliferator-activated receptor gamma)
metformin\pioglitazone\exenatide	metformin\pioglitazone\exenatide	The University of Texas Health Science Center at San Antonio	marketed	Combination antidiabetic agent (biguanide + thiazolidinedione + GLP-1 receptor agonist)	Multiple: AMPK pathway (metformin), PPAR-γ (pioglitazone), GLP-1 receptor (exenatide)
Pioglitazone + Metformin	Pioglitazone + Metformin	Sun Yat-sen University	marketed	Thiazolidinedione + Biguanide combination	PPAR-γ (pioglitazone); AMPK/mitochondrial complex I (metformin)
Rosiglitazone/alpha-lipoic acid	Rosiglitazone/alpha-lipoic acid	Seoul St. Mary's Hospital	marketed	Thiazolidinedione + antioxidant combination	PPAR-γ (rosiglitazone); mitochondrial oxidative stress (alpha-lipoic acid)
Dapagliflozin/Pioglitazone	Dapagliflozin/Pioglitazone	Boryung Pharmaceutical Co., Ltd	marketed	SGLT2 inhibitor / Thiazolidinedione combination	SGLT2 / PPAR-γ

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thiazolidinedione class)

Merck Sharp & Dohme LLC · 3 drugs in this class
GlaxoSmithKline · 1 drug in this class
Medical University of South Carolina · 1 drug in this class
National Cheng-Kung University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). rosiglitazone (4 mg)/day — Competitive Intelligence Brief. https://druglandscape.com/ci/rosiglitazone-4-mg-day. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab